CCL18

Материал из hpluswiki
Перейти к навигации Перейти к поиску

C-C motif chemokine 18 precursor (Alternative macrophage activation-associated CC chemokine 1) (AMAC-1) (CC chemokine PARC) (Dendritic cell chemokine 1) (DC-CK1) (Macrophage inflammatory protein 4) (MIP-4) (Pulmonary and activation-regulated chemokine) (Small-inducible cytokine A18) [Contains: CCL18(1-68); CCL18(3-69); CCL18(4-69)] [AMAC1] [DCCK1] [MIP4] [PARC] [SCYA18]

Publications[править]

Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.

Atopic dermatitis (AD) shows differential clinical presentation in older compared with younger patients. Nevertheless, changes in the AD molecular profile with age are unknown. We sought to characterize age-related changes in the AD profile. We evaluated age-specific changes in lesional and nonlesional tissues and blood from patients with moderate-to-severe AD (n = 246) and age-matched control subjects (n = 71) using immunohistochemistry, quantitative real-time PCR, and Singulex in a cross-sectional study. Patients were analyzed by age group (18-40, 41-60, and ≥61 years). Although disease severity/SCORAD scores were similar across AD age groups (mean, approximately 60 years; P = .873), dendritic cell infiltrates (CD1b and FcεRI , P < .05) decreased with age. T 2 measures (IL5, IL13, CCL13, CCL18, and CCL26) significantly decreased with age in patients with AD, despite increasing with age in control subjects. Consistent with T 2 axis decreases, serum IgE levels and eosinophil counts negatively correlated with age in patients with AD (r = -0.24 and r = -0.23, respectively; P < .05). T 22-secreted IL22 expression levels also decreased with age uniquely in patients with AD (P < .05). Expression of T 1-related (IFNG, IL12/23p40, STAT1, and CXCL9; P < .05 for CXCL9) and T 17-related (IL17A and IL20; P < .05 for IL20) markers increased with age in both patients with AD and control subjects. Expression of terminal differentiation measures significantly increased in older patients with AD (loricrin [LOR] and filaggrin [FLG], P < .05), whereas expression of S100As (S100A8, P < .01) and hyperplasia markers (epidermal thickness, keratin 16, and Ki67; P < .05 for keratin 16) decreased. Serum trends in AD mimicked skin findings, with T 2 downregulation (CCL26; r = -0.32, P < .1) and T 1 upregulation (IFN-γ; r = 0.48, P < .01) with age. The adult AD profile varies with age. Although T 1/T 17 skewing increases in both patients with AD and control subjects, patients with AD show unique decreases in T 2/T 22 polarization and normalization of epithelial abnormalities. Thus age-specific treatment approaches might be beneficial for AD.

MeSH Terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Aging
  • Cytokines
  • Dermatitis, Atopic
  • Female
  • Gene Expression
  • Humans
  • Male
  • Middle Aged
  • Phenotype
  • Severity of Illness Index
  • Skin
  • Young Adult

Keywords

  • Atopic dermatitis
  • T(H)1
  • T(H)17
  • T(H)2
  • T(H)22
  • aging
  • biomarker
  • filaggrin
  • hyperplasia
  • loricrin
  • skin